

Salva R Yurista

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1977075/publications.pdf>

Version: 2024-02-01

15
papers

633
citations

1040056

9
h-index

996975

15
g-index

18
all docs

18
docs citations

18
times ranked

819
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. <i>European Journal of Heart Failure</i> , 2019, 21, 862-873.	7.1	236
2	Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1660-1669.	2.8	111
3	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007684.	3.9	87
4	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. <i>JACC Basic To Translational Science</i> , 2019, 4, 831-840.	4.1	65
5	Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?. <i>Cardiovascular Diabetology</i> , 2020, 19, 5.	6.8	29
6	Ketone bodies for the failing heart: fuels that can fix the engine?. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 814-826.	7.1	26
7	SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. <i>Journal of Lipid and Atherosclerosis</i> , 2022, 11, 1.	3.5	25
8	Targeting Myocardial Substrate Metabolism in the Failing Heart: Ready for Prime Time?. <i>Current Heart Failure Reports</i> , 2022, 19, 180-190.	3.3	11
9	Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empagliflozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 311-321.	2.6	10
10	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. <i>Pflügers Archiv European Journal of Physiology</i> , 2021, 473, 1301-1313.	2.8	10
11	ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca ²⁺ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKII β . <i>International Journal of Molecular Sciences</i> , 2021, 22, 4427.	4.1	9
12	Ketone Bodies. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1433-1436.	2.8	5
13	Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 35, 953-963.	2.6	4
14	Magnetic resonance imaging of cardiac metabolism in heart failure: how far have we come?. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1277-1289.	1.2	2
15	Exercise-induced CITED4 expression is necessary for regional remodeling of cardiac microstructural tissue helicity. <i>Communications Biology</i> , 2022, 5, .	4.4	2